This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment

This study has been completed.
Information provided by:
Sanwa Kagaku Kenkyusho Co., Ltd. Identifier:
First received: September 13, 2005
Last updated: September 20, 2006
Last verified: September 2006
The purpose of this study is evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus with treated insulin.

Condition Intervention Phase
Type 2 Diabetes Mellitus Drug: Miglitol Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Sanwa Kagaku Kenkyusho Co., Ltd.:


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type2 diabetes
  • Criteria of postprandial plasma glucose and HbA1c are met

Exclusion Criteria:

  • Type1 diabetes
  • Patients with antidiabetic drugs
  • The other exclusion criteria are met
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00213070

Aichi, Japan
Chiba, Japan
Fukuoka, Japan
Gifu, Japan
Gunma, Japan
Hokkaido, Japan
Ibaraki, Japan
Kagoshima, Japan
Kanagawa, Japan
Kumamoto, Japan
Miyazaki, Japan
Oita, Japan
Okinawa, Japan
Saitama, Japan
Shiga, Japan
Tokyo, Japan
Sponsors and Collaborators
Sanwa Kagaku Kenkyusho Co., Ltd.
Study Director: Clinical Promotion Group Sanwa Kagaku Kenkyusho Co., Ltd.
  More Information Identifier: NCT00213070     History of Changes
Other Study ID Numbers: MG1005
Study First Received: September 13, 2005
Last Updated: September 20, 2006

Keywords provided by Sanwa Kagaku Kenkyusho Co., Ltd.:
alpha-glucosidase inhibitor,Insulin

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents
Physiological Effects of Drugs
Glycoside Hydrolase Inhibitors processed this record on August 18, 2017